CS Diagnostics Corp. (OTCQB: CSDX) Aligns Capital and Structure for 2026 Expansion

CS Diagnostics Corp. (OTCQB: CSDX), a medical technology company developing advanced diagnostic, wellness, and pharmaceutical solutions, has taken two transformative steps that strengthen its balance sheet, unify its affiliates, and position the company for accelerated growth and transparency heading into 2026.

Structural Simplification Fuels Consolidation Path

CSDX confirmed that its affiliates - CS Interpharm and CS Diagnostics Pharma - have completed the conversion of all Series B Preferred Stock holdings into unrestricted common stock. The move eliminates preferred dividend tracking and simplifies the capital structure ahead of CSDX's targeted full financial consolidation by December 31, 2025.

Principal Financial Officer Mohammad EsSayed called the milestone "a forward-thinking initiative that cements unity, innovation, and sustainable growth.""By integrating our affiliates' equity and operations, we're creating a single, transparent organization ready to compete and collaborate on the global stage," EsSayed said.

The consolidated framework will integrate revenues from diagnostics, wellness, and pharmaceutical products, providing investors a clear, unified view of group-wide performance.

Reg D 506(c) Offering Targets Commercial Scale-Up

Complementing the share conversion, CSDX has launched a Regulation D, Rule 506(c) investment offering, open to U.S. accredited and non-U.S. investors. The offering supports commercialization of its flagship innovations:

*
CS Protect Hydrogel - a next-generation radiotherapy tissue spacer gel improving precision and patient safety.

*
MEDUSA - an advanced surface disinfectant platform delivering scalable, hospital-grade infection control.

Proceeds will fund FDA/EPA filings, manufacturing expansion, and international sales infrastructure. Approximately 20-25% of capital is earmarked for regulatory filings, another 20-25% for sales and marketing, with the remainder allocated to R&D, quality systems, and digital investor-security platforms.

Positioned for 2026 Growth, Profitability, and Uplisting

Together, the offering and share conversion align governance, capital access, and operational focus - a trifecta that enhances CSDX's attractiveness to strategic partners and institutional investors. The company expects these initiatives to:

*
Accelerate commercialization of medical and wellness products.

*
Streamline financial reporting across the CS Group network.

*
Reinforce market confidence through transparency and compliance.

*
Lay groundwork for potential uplisting and global partnerships in 2026.

"We view 2025 as the bridge year to a consolidated, revenue-scaling 2026," added EsSayed. "Our roadmap is clear: unify, commercialize, and grow."

CS Diagnostics Corp. (OTCQB: CSDX) is a medical technology innovator developing products and pharmaceuticals that enhance patient safety, infection control, and diagnostic precision. The company's technologies-including CS Protect Hydrogel and MEDUSA-reflect its mission to improve global health outcomes through science, transparency, and innovation.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cs-diagnostics-corp-otcqb-csdx-aligns-capital-and-structure-for-2026-expansion]
Country: United States
Website: http://www.thestreetreports.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.